1 results for Albert, I
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Lara, PN; Douillard, JY; Nakagawa, K; von Pawel, J; McKeage, Mark; Albert, I; Losonczy, G; Reck, M; Heo, DS; Fan, X; Fandi, A; Scagliotti, G (2011)
The University of Auckland Library
This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non-small-cell lung cancer (NSCLC) versus chemotherapy alone.View record details